Author(s):
Ramya Kuber Banoth, Poojitha Nalluri, Swetha Addanki, Theja Indireddy, Jeeva Soundarajan
Email(s):
ramyakuber.spmvv@gmail.com
DOI:
10.52711/0974-360X.2025.00083
Address:
Ramya Kuber Banoth1*, Poojitha Nalluri2, Swetha Addanki3, Theja Indireddy4, Jeeva Soundarajan5
1Faculty of Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam (Women’s University), Tirupati, 517502, Andhra Pradesh, India.
2,5Student of Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam (Women’s university), Tirupati, 517502, Andhra Pradesh, India.
3Faculty of Department of Pharmaceutical Analysis, Mallareddy Pharmacy College, Secunderabad, India.
4Faculty of Department of Pharmaceutical Analysis, Nirmala College of Pharmacy, Kadapa, A.P., India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 2,
Year - 2025
ABSTRACT:
Reverse phase isocratic liquid chromatography (RP-HPLC) is a technique that is simple, specific, exact, and sensitive. The main objective of this research work is to develop and validate RP-HPLC and then perform stability studies on Pharmakon and formulations for the evaluation of Tepotinib. Successful chromatographic elution of Tepotinib was achieved on column Kromosil C18, (4.6 x 150) mm, 5µm, with a movable phase comprises of 1% Orthophosphoric acid: Acetonitrile (70:30 v/v). The detecting wavelength for Tepotinib evaluation was preferred at 308nm with run time at 1.0ml/min and volume of injection is 10µl. Tepotinib linearity was attained with a correlation coefficient of 0.999 at concentration between 5.625-33.75µg/ml. The elution time for Tepotinib was found to be 2.492 minutes using a 5mins run time. According to ICH criteria, the developed method has been validated for a numerous analytical parameter like specificity, linearity, limit of detection (LOD) and limit of quantification (LOQ), precision, accuracy and robustness. The validation's results showed outstanding agreement with the permitted range. The experiment's outcomes proved that the proposed technology is appropriate for routine evaluation and quality control of pharmaceutical formulations that contain active drugs.
Cite this article:
Ramya Kuber Banoth, Poojitha Nalluri, Swetha Addanki, Theja Indireddy, Jeeva Soundarajan. A Novel Stability Indicating RP-HPLC Analytical Method Development and Validation for the Determination of Tepotinib in Bulk and Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology.2025;18(2):557-2. doi: 10.52711/0974-360X.2025.00083
Cite(Electronic):
Ramya Kuber Banoth, Poojitha Nalluri, Swetha Addanki, Theja Indireddy, Jeeva Soundarajan. A Novel Stability Indicating RP-HPLC Analytical Method Development and Validation for the Determination of Tepotinib in Bulk and Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology.2025;18(2):557-2. doi: 10.52711/0974-360X.2025.00083 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-2-15
REFERENCES:
1. Afroz Patan, Reeyaz Basha S., et.al. Development and Validation of New RP- HPLC Method for theSimultaneous Estimation of Metformin Hydrochloride and Repaglinide in Pure and Pharmaceutical Formulations. Research Journal of. Pharmacy and Technology. 2021; 14(3): 1323-1328. doi: 10.5958/0974-360X.2021.00235.3
2. Brazel, D., Zhang, S., Nagasaka, M., Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. Lung Cancer: Targets and Therapy. 2022; 13: 33-35.
3. Drugbank.com, Tepotinib.https://go.drugbank.com/drugs/DB08828
4. Le X., et.al. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice VISION: Tepotinib Outcomes in METex14 Skipping NSCLC. Clinical Cancer Research. 2022; 28: 117-1126.
5. Takamori S,et.al. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation. Thoracic Cancer. 2021; 12: 978-980.
6. Monika Maheshwari and Parul Soni. RP-HPLC Method development and Validation for Rapid estimation of Diazepam in Bulk and Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology. 2022; 15(5): 1938-2. doi: 10.52711/0974-360X.2022.00322
7. ICH, Q2 (R1) Validation of Analytical Procedures: Text and Methodology, Proceedings of the International Conference on Harmonization, November 2005.
8. ICH, Q1A (R2) Stability Testing of New Drug Substances and Products, Proceedings of the International Conference on Harmonization, November 2003.